Anuh Pharma gains key European quality certification for sulfadimethoxine

Anuh Pharma Limited announced on December 5, 2025, that it has been granted the Certificate of Suitability (CEP) for Sulfadimethoxine by the European Directorate for the Quality of Medicines & HealthCare (EDQM). This approval underscores the company's commitment to delivering high-quality Active Pharmaceutical Ingredients (APIs) that meet stringent global regulatory standards.

The CEP for Sulfadimethoxine is expected to facilitate expanded access to regulated markets. This will support Anuh Pharma's customers by offering enhanced reliability, compliance, and supply security for the crucial ingredient.

Further details regarding this disclosure are available on Anuh Pharma's official website. The company has requested that this announcement be taken on record by both the BSE Limited and the National Stock Exchange of India Limited.